Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 1, 2004, Pages 11-20

  Chua, Daniel T T ^a,b   Nicholls, John M ^a   Sham, Jonathan S T ^a   Au, Gordon K H ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Epidermal growth factor receptor; Induction chemotherapy; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

BIOPSY; CARCINOGENS; CHEMOTHERAPY; CORRELATION METHODS; GROWTH KINETICS; PATIENT MONITORING; RADIOTHERAPY; STATISTICAL METHODS; TUMORS;

EPIDERMAL GROWTH; INDUCTION CHEMOTHERAPY; NODAL SIZE; PROGNOSTIC VALUE;

ONCOLOGY;

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; EPIRUBICIN; FEMALE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4644345181     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.038     Document Type: Article

References (27)

1. Salomon D.S., Brandt R., Ciardello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232.
2. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250.
3. Santini J., Formento J.L., Francoual M., et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 13:1991;132-139.
4. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 11:1993;1873-1878.
5. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62:2002;7350-7356.
6. Zheng X., Hu L., Chen F., et al. Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol. 30B:1994;290-295.
7. Fujii M., Yamashita T., Ishiguro R., et al. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx. 29:2002;175-181.
8. Ho J.H. Nasopharynx. Halnan K.E. Treatment of cancer. 1982;249-267 Chapman and Hall, London.
9. Keasley J.H., Leonard J.H., Walsh M.D., et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinoma. Pathology. 23:1991;189-194.
10. Putti T.C., To K.F., Hsu H.C., et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression A multicentre immunohistochemical study in the Asia-Pacific region. Histopathology. 41:2002;144-151.
11. Wen Q.H., Miwa T., Yoshizaki T., et al. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope. 106:1996;884-888.
12. Lee C.S., Redshaw A., Boag G. Epidermal growth factor immunoreactivity in human laryngeal squamous cell carcinoma. Pathology. 29:1997;251-254.
13. Grandis J.R., Melhem M.F., Barnes E.L., et al. Quantitative immunohistochemistry analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 78:1996;1284-1292.
14. Maurizi M., Almadori G., Ferrandina G., et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 74:1996;1253-1257.
15. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:1998;824-832.
16. Sheen T.S., Huang Y.T., Chang Y.L., et al. Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res. 90:1999;1285-1292.
17. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:1999;2884-2890.
18. Sheridan M.T., O'Dwyer T., Seymour C.B., et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest. 5:1997;180-186.
19. Roychowdhury D.F., Tseng A. Jr, Fu K.K., et al. New prognostic factors in nasopharyngeal carcinoma Tumor angiogenesis and C-erbB2 expression. Cancer. 77:1996;1419-1426.
20. International Nasopharynx Cancer Study Group. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma A positive effect on progression-free survival - VUMCA I trial. Int J Radiat Oncol Biol Phys. 35:1996;463-469.
21. Chua D.T., Sham J.S., Choy D., et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 83:1998;2270-2283.
22. Ma J., Mai H., Hong M., et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 19:2001;1350-1357.
23. Rossi A., Molinari R., Boracchi P., et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer Results of a 4-year multicenter randomized study. J Clin Oncol. 6:1988;1401-1410.
24. Chan A.T., Teo P.M., Leung T.W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 33:1995;569-577.
25. Al Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer Phase III randomized Intergroup study 0099. J Clin Oncol. 16:1998;1310-1317.
26. Lin J.C., Jan J.S., Hsu C.Y., et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma Positive effect on overall and progression-free survival. J Clin Oncol. 21:2003;631-637.
27. Chan A.T., Teo P.M., Ngan R.K., et al. Concurrent chemotherapy- radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma Progression free survival analysis of a phase III randomized trial. J Clin Oncol. 20:2002;2038-2044.